• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioInvent reorganizes after TB-402 bust

BioInvent reorganizes after TB-402 bust

June 29, 2012
CenterWatch Staff

BioInvent International, a Swedish research-based pharmaceutical company that focuses on developing antibody drugs, has decided to initiate negotiations with trade unions regarding organizational changes due to halting development of the antithrombotic agent TB‑402.

The negotiations are in accordance with the Swedish Co-Determination Act in respect of the planned personnel changes. Once negotiations are complete, a final decision will be taken on the relevant organizational and personnel matters.

The new organization is planned to employ 68 full-time personnel, a decrease from the current 89. The reduction in work force and other reprioritizations are expected to result in cost savings of around $2.1 million on a full-year basis, fully effective from January 2013.

“We regret the fact that the changes in our organization will impact a number of our employees, but consider it necessary to take better advantage of the opportunities provided by positive study data later this year,” said Svein Mathisen, president and CEO of BioInvent. “We are now focusing our resources on the most promising projects, for which we expect to present study results in two of the most advanced projects during the forthcoming quarter.

The company's resources will be reprioritized to focus on the continued development of BI‑204 for the treatment of acute coronary artery disease and new and existing cancer projects such as BI‑505.

“The combined project portfolio with proprietary projects and with projects run by our partners provides a solid foundation for long term growth and to create shareholder value,” added Mathisen.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing